Pfizer Q2 2022 Earnings Report Recap

PFE beat on earnings and on revenue

Key Takeaways

  • Pfizer's earnings and revenue solidly beat consensus estimates.
  • The company's vaccines business, including its COVID-19 vaccine, generated $10.5 billion in revenue for the quarter.
  • Pfizer expects that its COVID-19 vaccine and oral antiviral treatment against the disease will generate a total of roughly $54 billion in combined revenue for FY 2022.

Pfizer Earnings Results
Metric Beat/Miss/Match Reported Value Analysts' Prediction
Adjusted EPS Beat $2.04 $1.68
Revenue Beat $27.7B $25.5B

Source: Predictions based on analysts' consensus from Visible Alpha

Pfizer (PFE) Financial Results: Analysis

Pfizer Inc. (PFE) reported Q2 FY 2022 earnings results that solidly surpassed analyst expectations. Adjusted earnings per share (EPS) surged by 92.5% relative to the year-ago quarter, beating expectations by a wide margin. Pfizer's revenue grew by 46.8% year-over-year (YOY). While this was a slower pace of growth in this area than the last quarter on a sequential basis, revenue nonetheless also far exceeded analyst expectations. Approximately 37.7% of this revenue was from vaccine sales, including sales of the company's COVID-19 vaccine, developed with German-based BioNTech SE (BNTX).

PFE COVID-19 Vaccine

A significant contribution to Pfizer's revenue growth came from its vaccine business, including sales of two products related to COVID-19: Comirnaty, the company's vaccine against the disease; and Paxlovid, its oral antiviral treatment against COVID-19. Paxlovid contributed $8.1 billion in worldwide sales for the quarter. Excluding sales from Comirnaty and Paxlovid, Pfizer's revenue increased 1% operationally (operational revenue excludes the impact of foreign exchange rates).

Paxlovid received emergency use authorization (EUA) by the Food and Drug Administration (FDA) in December 2021. It is a prescription-only medication used for treating cases of COVID-19 in adults and pediatric patients at least 12 years of age or weighing at least 88 pounds. It is the first oral antiviral treatment for COVID-19 to receive EUA. In June, Pfizer submitted a New Drug Application (NDA) to the FDA for Paxlovid for the treatment of patients at high risk of severe illness from COVID-19, consistent with the current EUA.

Pfizer, in collaboration with BioNTech, was also the first company to receive an EUA from the FDA for its vaccine. In August 2021, it also became the first company to gain full approval from the FDA for use of its vaccine in individuals 16 years of age or older. In October, the FDA authorized the Pfizer-BioNTech vaccine for emergency use by millions of children 5 through 11 years of age. The FDA approved at the end of March a second booster dose of the vaccine for people 50 years of age and older and certain immunocompromised individuals. In June, the FDA authorized Comirnaty for emergency use by children as young as 6 months of age.

PFE Outlook and Stock Performance

Pfizer affirmed its FY 2022 guidance for Comirnaty and Paxlovid revenue of roughly $32 billion and $22 billion, respectively. It raised its operational guidance for total revenue and adjusted EPS for FY 2022 by about $2 billion and 24 cents, respectively. Including the impact of foreign exchange rates, the company's guidance for revenue remains $98 billion to $102 billion, while the guidance for adjusted EPS becomes $6.30 to $6.45, adjusted slightly from $6.25 to $6.45.

PFE Conference Call Recap

In an earnings call after results were announced, Pfizer Chief Executive Officer (CEO) Albert Bourla indicated that his company will continue to see strong demand for its Covid-19 treatments.

“After 2½ long years, like everyone else, we would hope that this global health crisis would be over soon,” Bourla said. “But as much as hope is important, hope is not science. And science is telling us that Covid-19 likely will remain a major global healthcare concern for years to come." The company said it is focusing on developing the next generation of Covid-19 vaccines as well as new uses for existing Covid-19 products.

After briefly rising, Pfizer shares traded roughly sideways in pre-market trading hours July 28 after the company's earnings report. The company's stock has provided a 1-year trailing total return of 27.6%, well ahead of the -8.6% total return of the S&P 500, as of July 28.

Pfizer's next earnings report (for Q3 FY 2022) is expected to be released on Nov. 1, 2022.

Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.
  1. Visible Alpha. "Financial Data."


  3. Food and Drug Administration. "Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19."

  4. Food and Drug Administration. "FDA Takes Key Action in Fight Against COVID-19 by Issuing Emergency Use Authorization for First COVID-19 Vaccine."

  5. Food and Drug Administration. "FDA Approves First COVID-19 Vaccine."

  6. Food and Drug Administration. "FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age."

  7. Food and Drug Administration. "Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals."

  8. Food and Drug Administration. "Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age."

  9. Wall Street Journal. "Pfizer Sales Climb Again on Covid-19 Products."

  10. Wall Street Journal. "Pfizer Sales Climb Again on Covid-19 Products."

  11. TradingView. "Price Chart: PFE and S&P 500."

  12. MarketScreener. "PFIZER, INC. (PFE)."

Take the Next Step to Invest
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.